menu
    • menu
    [{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Bacteria-based Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":"3","companyTruncated":"Ancilia Bioscience \/ Safar Partners"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Bacterial Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ancilia Bioscience \/ ARPA-H","highestDevelopmentStatusID":"4","companyTruncated":"Ancilia Bioscience \/ ARPA-H"}]

    Find Clinical Drug Pipeline Developments & Deals by Ancilia Bioscience

    Menu

    Ancilia Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ancilia Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Ancilia Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacterial Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : ARPA-H

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Ancilia Biosciences Wins $3M Award from ARPA-H for Women's Health

                            Details : The funding will enable the company to complete preclinical testing and advance its lead therapeutic candidate through IND submission for a first-in-human clinical trial.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Bacterial Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : ARPA-H

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ancilia Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Ancilia Bioscience

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacteria-based Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Safar Partners

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ancilia Biosciences Announces Closing of $4.2 Million Financing

                            Details : The financing supports development of Ancilia’s platform that harnesses CRISPR’s natural function to increase the utility of live bacterial products against viruses.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 17, 2024

                            Lead Product(s) : Bacteria-based Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Safar Partners

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth